Cart
sales@molnova.com
JHU395
CAS No. 2079938-92-2
JHU395( —— )
Catalog No. M32972 CAS No. 2079938-92-2
JHU395 is an orally-bioavailable prodrug of a lipophilic glutamine antagonist (GA), 6-diazo-5-oxo-L-norleucine (DON).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 242 | In Stock |
|
| 25MG | 464 | In Stock |
|
| 50MG | 709 | In Stock |
|
| 100MG | 1079 | In Stock |
|
| 200MG | 1451 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJHU395
-
NoteResearch use only, not for human use.
-
Brief DescriptionJHU395 is an orally-bioavailable prodrug of a lipophilic glutamine antagonist (GA), 6-diazo-5-oxo-L-norleucine (DON).
-
DescriptionJHU395 is an orally-bioavailable and a plasma stable lipophilic glutamine antagonists (GA) proagent. JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2079938-92-2
-
Formula Weight447.48
-
Molecular FormulaC22H29N3O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (223.47 mM; Ultrasonic )
-
SMILESC(OC(C(C)(C)C)=O)(OC(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)C1=CC=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lemberg KM, et al. The novel glutamine antagonist prodrug JHU395 has antitumor activity in malignant peripheralnerve sheath tumor. Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0319.2019.?
molnova catalog
related products
-
Ac-DEVD-CHO
Ac-DEVD-CHO is a specific Caspase-3 inhibitor (Ki: 230 pM) with inhibitory effects on SLNT-induced apoptosis.
-
TJ08
TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells.
-
HNPMI
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
